January 21, 2024
Adagrasib as Monotherapy or With Cetuximab for KRAS-Mutated Colorectal Cancer
A phase 1–2 clinical trial found that adagrasib combined with cetuximab in patients with KRAS G12C mutations can increase progression-free survival and overall survival in refractory colorectal cancer patients. There is a pressing need for effective treatments for metastatic colorectal cancer, particularly for patients with the KRAS G12C mutation, a kind of colorectal cancer that...
Managing Refractory Colorectal Cancer With Trifluridine–Tipiracil Plus Bevacizumab
A phase 3 clinical trial confirms that combination therapy with trifluridine–tipiracil plus bevacizumab is associated with better clinical outcomes in refractory colorectal cancer cases than trifluridine–tipiracil monotherapy. First-line and second-line treatment of colorectal cancer includes chemotherapy with fluorouracil-based agents (oxaliplatin and irinotecan) along with newer vascular endothelial growth factor (VEGF)-based therapy (mainly bevacizumab) and epidermal...
HIV-1 Lingers Despite Long-Term Treatment
HIV-1 cannot be cured even with decades of antiretroviral therapy. A new cohort study shows that the inducible, replication-competent reservoir does not decline even with prolonged antiretroviral therapy. Antiretroviral therapy (ART) has helped suppress the HIV-1 virus to almost undetectable levels among those who adhere to the treatment. There are many people living with HIV...
Pitavastatin Guards Heart Health in HIV
A new randomized clinical trial shows that pitavastatin or other statins may help reduce major cardiovascular events in those living with HIV. These benefits are not just due to LDL cholesterol reduction. HIV significantly increases atherosclerotic cardiovascular disease incidence in those living with HIV. Studies suggest that those living with HIV have twice the risk...
Pre-Exposure Prophylaxis for HIV Prevention: Updated Report
The 2023 updated report by the U.S. Preventive Services Task Force found that oral tenofovir alafenamide-emtricitabine or injectable cabotegravir were slightly superior to older tenofovir disoproxil fumarate-emtricitabine pre-exposure prophylaxis for HIV prevention. In 2019, the U.S. Preventive Services Task Force (USPSTF) report confirmed that oral pre-exposure prophylaxis (PrEP) using tenofovir disoproxil fumarate (TDF) alone or...